Liptruzet — Class III drug recall D-1312-2014
Terminated recall by Merck & Co Inc, reported 2014-05-14, distributed nationwide. Defective Container; some of the outer laminate foil pouches allowed in air and moisture, which could potentia
| Recall number | D-1312-2014 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Merck & Co Inc, Whitehouse Station, NJ, United States |
| Recall initiated | 2014-01-13 |
| Classified | 2014-05-06 |
| Reported by FDA | 2014-05-14 |
| Terminated | 2015-09-02 |
| Distributed | Nationwide (US) |
| Quantity | 11,462 cartons |
| Reason classes | packaging |
| NDC | 66582-0323-30, 66582-0323-54 |
Product
Liptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30), b) 90 count blister (NDC 66582-323-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
Reason for recall
Defective Container; some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1312-2014. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.